arrow
A

Anvar Hassan Kaleeckal

Hamad Medical Corporation
H指数:41
被引数:6,463

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study

评估COVID-19疫苗在不同流行病学设计中的有效性:一项全国性研究中测试阴性病例对照分析与回顾性队列分析的比较

2026-09-220
OAAI
Estimating SARS-CoV-2 infection incidence and detection rates: Demonstrating a novel surveillance method

估计SARS-CoV-2感染发病率和检测率:展示一种新型监测方法

2025-10-290
OAAI
Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis

评估卡塔尔COVID-19 mRNA基础系列疫苗接种的成本效益:一项整合流行病学和经济学的分析

2025-09-260
PRE
Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time

卡塔尔关于COVID-19疫苗一剂与两剂比较有效性的研究:证据显示保护效果随时间趋同

Vaccine
IF3.5
2025-07-290
OA
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities
2025-03-260
OAAI
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar

以住院数据为指标评估新型冠状病毒肺炎严重程度:卡塔尔全国评估

2025-02-170
OAAI
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar

BNT162b2与mRNA-1273疫苗: 卡塔尔长期预防SARS-CoV-2感染和严重新型冠状病毒肺炎的比较分析

2024-09-290
OA
Prevalence of hepatitis B and C viruses among migrant workers in Qatar

卡塔尔移民工人中乙型和丙型肝炎病毒的患病率

2024-05-176
OAAI
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

保护自然感染免受SARS-CoV-2 JN.1变体的再感染

2024-04-095
OAAI
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation

解决SARS-CoV-2再感染定义中的偏见: 低估的含义

2024-03-114
OAAI
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design

评估先前感染对预防再感染的保护作用: 应用测试阴性研究设计

2023-12-077
OAAI
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
2023-11-211
OA
History of primary-series and booster vaccination and protection against Omicron reinfection

初级系列和加强疫苗接种的历史以及对Omicron再感染的保护

2023-10-064
OAAI
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
2023-09-0123
OAAI
Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar
2023-08-224
OAAI
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

二价mRNA-1273.214疫苗对SARS-CoV-2 omicron XBB * 感染的有效性

2023-08-0910
OAAI
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
2023-08-017
OAAI
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

通过感染史,临床脆弱性和免疫印迹来提高新型冠状病毒肺炎的长期疗效: 一项基于人群的回顾性队列研究

2023-07-0141
OAAI
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents

BNT162b2抗原剂量与青少年SARS-CoV-2 omicron感染

2023-03-011
OAAI